Zhaoke Ophthalmology Ltd. (HK:6622)
:6622
Top Page
Zhaoke Ophthalmology Ltd.
(6622)
Select Model
Select Model
Rating:47Neutral
Price Target:
HK$3.50
▲(10.41% Upside)
Action:ReiteratedDate:11/19/25
Zhaoke Ophthalmology Ltd.'s overall stock score is primarily impacted by its financial performance, which shows revenue growth but persistent losses and negative cash flows. Technical analysis presents a neutral outlook, while valuation remains challenging due to negative earnings. The absence of earnings call data and corporate events limits further insights.
Positive Factors
Balance Sheet Strength
A strong equity base and low financial leverage provide durable financial stability, increasing the company's ability to fund multi-year R&D and commercialization cycles without heavy interest burdens. This reduces bankruptcy risk and supports strategic investment flexibility.
Negative Factors
Persistent Unprofitability
Ongoing negative profitability erodes retained earnings and limits internal funding for trials and commercialization. Over time, sustained operating losses increase reliance on external capital, heighten dilution risk, and constrain ability to demonstrate consistent free-cash-flow generation.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance Sheet Strength
A strong equity base and low financial leverage provide durable financial stability, increasing the company's ability to fund multi-year R&D and commercialization cycles without heavy interest burdens. This reduces bankruptcy risk and supports strategic investment flexibility.
Read all positive factors
Zhaoke Ophthalmology Ltd. (6622) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$1.67B
Dividend YieldN/A
Average Volume (3M)1.25M
Price to Earnings (P/E)―
Beta (1Y)1.40
Revenue Growth-38.38%
EPS Growth-22.12%
CountryHK
Employees294
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.18
Shares Outstanding548,749,000
10 Day Avg. Volume1,172,850
30 Day Avg. Volume1,251,992
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)0.32
Price to Sales (P/S)8.88
P/FCF Ratio-2.07
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.32
Revenue Forecast (FY)HK$421.50M
Zhaoke Ophthalmology Ltd. Business Overview & Revenue Model
Company Description
Zhaoke Ophthalmology Limited, an ophthalmic pharmaceutical company, engages in the research, development, and commercialization of therapies that address unmet medical needs in the People's Republic of China. It is developing various drugs that co...
How the Company Makes Money
Zhaoke Ophthalmology generates revenue primarily through the sale of its pharmaceutical products and medical devices. The company's revenue model is centered on the development and commercialization of proprietary drugs and therapies that address ...
Zhaoke Ophthalmology Ltd. Financial Statement Overview
Summary
Income Statement
40
Negative
Balance Sheet
65
Positive
Cash Flow
30
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 35.36M | 69.32M | 18.75M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 17.42M | 51.80M | 14.25M | 0.00 | 0.00 | -22.31M |
| EBITDA | -296.42M | -251.23M | -327.86M | -384.55M | -377.53M | -39.89M |
| Net Income | -278.31M | -237.49M | -385.04M | -407.32M | -2.13B | -816.90M |
Balance Sheet | ||||||
| Total Assets | 2.07B | 2.24B | 2.42B | 2.57B | 2.61B | 1.23B |
| Cash, Cash Equivalents and Short-Term Investments | 1.05B | 1.19B | 1.46B | 1.73B | 2.14B | 871.34M |
| Total Debt | 271.40M | 238.59M | 238.03M | 131.93M | 37.03M | 37.53M |
| Total Liabilities | 362.61M | 343.44M | 372.02M | 222.25M | 109.92M | 1.97B |
| Stockholders Equity | 1.71B | 1.90B | 2.05B | 2.35B | 2.50B | -745.97M |
Cash Flow | ||||||
| Free Cash Flow | -100.50M | -297.79M | -418.93M | -569.60M | -339.63M | -188.11M |
| Operating Cash Flow | -97.31M | -253.72M | -323.66M | -331.05M | -245.14M | -113.54M |
| Investing Cash Flow | -37.01M | -116.45M | -75.77M | -324.57M | 683.52M | -1.06B |
| Financing Cash Flow | 0.00 | -12.12M | 99.29M | 76.23M | 1.66B | 1.09B |
Zhaoke Ophthalmology Ltd. Technical Analysis
Neutral
3.17
Price Trends
3.29
Negative
3.26
Negative
3.30
Negative
Market Momentum
-0.09
Positive
43.96
Neutral
56.57
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6622, the sentiment is Neutral. The current price of 3.17 is above the 20-day moving average (MA) of 3.14, below the 50-day MA of 3.29, and below the 200-day MA of 3.30, indicating a bearish trend. The MACD of -0.09 indicates Positive momentum. The RSI at 43.96 is Neutral, neither overbought nor oversold. The STOCH value of 56.57 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:6622.
Zhaoke Ophthalmology Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | HK$9.37B | 20.83 | 4.47% | 4.28% | -8.49% | -9.46% | |
60 Neutral | HK$3.86B | -16.66 | 0.99% | ― | 9.41% | -32.69% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | HK$1.67B | -4.01 | -12.64% | ― | -38.38% | -22.12% | |
47 Neutral | HK$6.98B | -34.12 | -4.32% | ― | 74.73% | 32.13% | |
44 Neutral | HK$1.01B | -18.55 | -15.19% | ― | ― | 22.65% | |
43 Neutral | HK$1.68B | -6.43 | 293.08% | ― | ― | 27.90% |
* Healthcare Sector Average
HK:6622
Zhaoke Ophthalmology Ltd.
3.04
1.58
108.22%
HK:1477
Ocumension Therapeutics
8.56
4.25
98.61%
HK:1875
TOT BIOPHARM International Co. Ltd.
5.00
3.41
214.47%
HK:2185
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H
4.13
2.27
122.04%
HK:6826
Shanghai Haohai Biological Technology Co., Ltd. Class H
22.24
0.75
3.49%
HK:6978
Immunotech Biopharm Ltd
2.72
-0.40
-12.82%
Zhaoke Ophthalmology Ltd. Corporate Events
Zhaoke Ophthalmology Set to Accelerate Asia-Pacific Launch After Partner’s FDA Approval for Presbyopia Drug
Jan 29, 2026
Zhaoke Ophthalmology announced that its partner Tenpoint Therapeutics has received U.S. FDA approval for YUVEZZI (formerly BRIMOCHOL PF), a preservative-free, once-daily dual-agent eye drop for the treatment of presbyopia, following successful Pha...
Zhaoke Ophthalmology Expands BRIMOCHOL™ PF Presbyopia Push to Singapore and Vietnam
Jan 26, 2026
Zhaoke Ophthalmology has expanded its commercialization strategy for its core presbyopia candidate BRIMOCHOL™ PF by granting exclusive distribution rights to AFT Pharmaceuticals in Singapore and Senju Pharmaceutical in Vietnam, covering regi...
Zhaoke Ophthalmology’s Pediatric Myopia Drug Accepted for Evaluation by Australia’s TGA
Jan 13, 2026
Zhaoke Ophthalmology has announced that Australia’s Therapeutic Goods Administration has accepted for evaluation its registration application for Atropine Sulfate Eye Drops (0.01% NVK002), an investigational treatment aimed at controlling my...
Zhaoke Ophthalmology Partners with TSH Biopharm for Taiwan Market Entry
Dec 8, 2025
Zhaoke Ophthalmology Ltd. has entered a strategic partnership with TSH Biopharm to commercialize BRIMOCHOL™ PF in Taiwan. This partnership allows TSH Biopharm to register, import, and market the presbyopia-correcting eyedrop, potentially enh...
Zhaoke Ophthalmology Gains Key Approvals for Innovative Eye Treatments
Nov 24, 2025
Zhaoke Ophthalmology Limited announced the approval of its Investigational New Drug application for PAN-90806, an innovative eye drop for treating wet age-related macular degeneration, by China’s National Medical Products Administration. Add...
Zhaoke Ophthalmology Expands into Indonesia with New Distribution Agreement
Nov 6, 2025
Zhaoke Ophthalmology Ltd. has entered into a distribution agreement with PT Ferron Par Pharmaceuticals to commercialize BRIMOCHOL™ PF, an innovative presbyopia treatment, in Indonesia. This strategic move grants PT Ferron exclusive rights to...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.